Since the discovery of oncogenic receptor by George Zhu from oncogenic pml/RARa fusion in the etiology of a specific APL and androgen/ oncogenic androgen receptor signaling in hormonal tumorigenesis in 1989s [1-7], many studies are dedicated on their clinical targeting therapy. At present, thousands of publications and over 100 global journals cited this scientific terminology ‘oncogenic receptor and its target therapy or oncogenic receptor (tyrosine) kinase in tumours. The traditionally accepted view is that normal epidermal growth factor receptor (EGFR) is no tumorigenic [8]. Epidermal growth factor (EGF) consists of 53 amino acids residues and contain intramolecular disulfide bonds that are required for its biological activity [9-11]. EGF can stimulate or inhibit proliferation and differentiation in a wide variety of cells, e.g. epidermal cells, corneal epithelial cells, fibroblasts, myofibroblasts, keratocytes and angiogenesis. EGF is thought play a fundamental role in body tissue during development ad in the adult. EGF interact with a specific EGF receptor which located at the cell surface [12]. Recently, it has been indicated that EGF was found to exert its effects on superficial burn [13,14], wound healing, diabetic foot ulcer [15,16] and break a novel therapeutic strategy. In addition, cosmetics rich in EGF have the advantages of wrinkle removal, whitening, skin elasticity and anti-skin aging and in the amount of erythema and sebum control on skin care. In this regard, George Zhu and Zhi QW [11] in this field have successfully prepared a series of 68 bottles of Shampoo liquid (New Washing) and 20 bottles of recombinant human EGF (rhEGF) spray, and 3 bottles of EGF-Silvadene ointment into market. The initial results indicated that prepared rhEGF is safe and available in clinical wound healing and this may assist wound healing time.

References

1. Zhu G. “Oncogenic receptor hypothesis (1989-91)”. VOA (Voice of America) 12 (1992): 31.
2. Zhu G., et al. “Induction of thyroid neoplasm following plant medicine marine algae (sargassum): a rare case and literature”. Current Pharmaceutical Biotechnology 9 (2013): 859-863.
3. Zhu G., et al. “Novel treatment of acute promyelocytic leukemia: As2O3, retinoic acid and retinoid pharmacology”. Current Pharmaceutical Biotechnology 14 (2013): 849-858.
4. Zhu G., et al. “Downregulating oncogenic receptor: from bench to clinic”. Hematology and Medical Oncology 1 (2016): 30-40.
5. Zhu G. “Ep CAM- an old cancer antigen, turned oncogenic receptor and its targeting immunotherapy”. Universal Journal of Pharmaceutical Research 2 (2018): 41-46.
6. Zhu G. “Treatment of patients with advanced cancer following chemotherapy and traditional medicine- long term follow up of 75 cases”. Universal Journal of Pharmaceutical Research 3 (2018): 10-18.
7. Zhu G. “Vitamin A and its derivatives- retinoic acid and retinoid pharmacology”. American Journal of Biomedical Science and Research 2 (2019): 162-177.
8. Tang CK., et al. “Epidermal growth factor receptor vIII enhances tumorigenicity in human breast cancer”. Cancer Research 11 (2000): 3081-3087.
9. Cohen S. “Isolation of a mouse submaxillary gland protein accelerating incisor eruption and eyelid opening in the new-born animal”. Journal of Biological Chemistry 237 (1962): 1555-
10. Gregory H. “Isolation and structure of urogastrone and its relationship in epidermal growth factor”. Nature 257 (1975): 325-
11. Zhu G., et al. “Enhancement of wound healing by topical application of epidermal growth factor in animal model”. Universal Journal of Pharmaceutical Research 1 (2020): 12-20.
12. Stoscheck CM and King LE. “Role of epidermal growth factor in carcinogenesis”. Cancer Research 3 (1986): 1030-1037.
13. Brown GL., et al. “Enhancement of wound healing by topical treatment with epidermal growth factor”. The New England Journal of Medicine 321 (1989): 76-
14. Wang SL., et al. “Effects of recombinant human epidermal growth factor on healing of chronic ulcer wound”. Chinese Journal of Traumatology 6 (1998): 348-349.
15. Afsbari M., et al. “Efficacy of topical epidermal growth factor in healing diabetic foot ulcer”. Therapy5 (2005): 759-765.
16. Wong WKR., et al. “Authentic human epidermal growth factor: A panacea for wound healing”. EC Endocrinology and Metabolic Research 4 (2018): 138-146.
17. Robinson B. “Tumor cells share oncogenic receptors”. The Journal of Cell Biology 181 (2008): 570.
18. O'Connor R. “Concealed cargo within the tumor microenvironment: microvesicles disseminate oncogenic receptors among cancer cells”. Cancer Biology and Therapy 7 (2008): 1350-13
19. Al-Nedawi K., et al. “Intracellular transfer of the oncogenic receptor EGFRvIII by microvesicles derived from tumour cells”. Nature Cell Biology 10 (2008): 619-
20. Yan T., et al. “Characterization of cancer stem-like cells derived from mouse induced pluripotent stem cells transformed by tumor-derived extra -cellular vesicle”. Journal of Cancer 7 (2014): 572-584.
21. Montermini L., et al. “Inhibition of oncogenic epidermal growth factor receptor kinase triggers release of exosome-like extracellular vesicle and impacts their phosphoprotein and DNA content”. Journal of Biological Chemistry 40 (2015): 24534-24546.
22. Chihara E., et al. “Chemo preventive effect of gefitinib on non-smoking-related lung tumorigenesis in activating epidermal growth factor receptor transgenic mice”. Cancer Research 69 (2009): 7088-
23. Greulich H., et al. “Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants”. PLOS Medicine 11 (2005): e313.
24. Lynch TJ., et al. “Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib”. The New England Journal of Medicine 21 (2004): 2129-2139.
25. Cross DA., et al. “AZD9291,an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer”. Cancer Discovery 9 (2014): 1046-1061.
26. Finlay MR., et al. “Discovery of a potent and selective EGFR inhibitor (AZD9291) of both sensitizing and T790M resistance mutations that spares the wild type form of the receptor”. Journal of Medicinal Chemistry 20 (2014): 8249-8267.
27. Konduri K., et al. “EGFR fusions as novel therapeutic targets in lung cancer”. Cancer Discovery 6 (2016): 601-
28. Zhu G., et al. “A pilot study of lung cancer following chemotherapy and traditional medicine: report of 12 cases”. Lungs and Breathing 1.3 (2017): 1-4.
29. Mok TS., et al. “Osimertinib or platinum-pemetrexed in EGFR T790M- positive lung cancer”. The New England Journal of Medicine 376 (2017): 629-
30. Rodriguez PC., et al. “Clinical development and perspectives of CIMAvax EGF, Cuban vaccine for non-small-cell lung cancer therapy”. MEDICC Review 1 (2010): 17-23.
31. Rodriguez PC., et al. “A phase III clinical trial of the epidermal growth factor vaccine CIMAvax-EGF as switch maintenance therapy in advanced non-small -cell lung cancer patients”. Clinical Cancer Research 15 (2016): 3782-3790.